Article
Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors.
Genes, chromosomes & cancer - 1 Apr 2017
Takahashi Tsuyoshi, Elzawahry Asmaa, Mimaki Sachiyo, Furukawa Eisaku, Nakatsuka Rie, Nakamura Hiromi, Nishigaki Takahiko, Serada Satoshi, Naka Tetsuji, Hirota Seiichi, Shibata Tatsuhiro, Tsuchihara Katsuya, Nishida Toshirou, Kato Mamoru
Abstract excerpt
Gastrointestinal stromal tumors represent the most common mesenchymal tumor of the digestive tract, driven by gain-of-function mutations in KIT. Despite its proven benefits, half of the patients treated with imatinib show disease progression within 2 years due to secondary resistance mutations in KIT. It remains unclear how the genomic and transcriptomic features change during the acquisition of imatinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.